Global Smart Inhalers Market was measured at US$ 37.4 million and is expected to hit US$ 1.5667 million by 2027 rising at a CAGR of 59.4% from 2021 to 2027. Smart Inhalers Market type of advanced inhaler that is digitally connected to apps on a phone or tablet, allowing clinicians to better manage a patient’s medical condition. Smart inhalers use Bluetooth technology to track inhaler usage, remind patients to take their prescription, and collect data to aid in care planning. Aside from respiratory disease treatment, the gadget also sends a smartphone notice when a patient reaches a high pollen or extremely polluted location, allowing the patient to select whether or not to enter the area. Smart inhalers include sensors that allow patients to automatically track how often they use their inhaler, eliminating the possibility of human error. Many countries’ public health systems have been overburdened as a result of the COVID-19 crisis, highlighting the critical need for long-term investment in health systems. As the COVID-19 epidemic spreads, the healthcare industry’s growth is projected to slow. The life sciences industry is booming thanks to rising demand for in vitro diagnostic products and increased research and development efforts around the world. However, sales in the medical technology and imaging industry are declining as a result of fewer procedures being performed and equipment procurement being delayed or postponed. In addition, after the pandemic, virtual consultations with healthcare specialists are likely to become the standard way of care delivery. Digital health will continue to grow in the coming years as telehealth transforms care delivery. Nowadays there are extensively available connected devices for asthma and COPD, particularly smart inhalers, which monitor and track drug use accurately. Smart inhalers are robust and accurate and respiratory inhalers currently available are inadequate for proper asthma and COPD care. Instead of simply offering incrementally better drugs, this scenario suggests that smart inhalers have new ways to deliver and enable patient self-management. For example, a swiss based company Sensirion has developed SDP3X which can be incorporated into smart inhalers. In 2019, collaboration between Novartis and Qualcomm, acquisition of Inspiro Medical by Opko Health, and acquisition of Gecko Health by Teva Pharmaceuticals for manufacturing smart inhalers. In September 2017, Adherium has received approval from FDA for its new Symbicort inhaler monitoring device SmartTouch for the Symbicort aerosol inhaler from AstraZeneca. In February 2017, Propeller Health collaborated with Novartis to develop a custom add-on sensor for the Breezhaler inhaler. In 2019, world’s first smart inhaler was approved by FDA-Teva’s ProAir Digihaler.